Canada markets open in 3 hours 23 minutes
  • S&P/TSX

    20,461.93
    +60.44 (+0.30%)
     
  • S&P 500

    4,448.98
    +53.34 (+1.21%)
     
  • DOW

    34,764.82
    +506.50 (+1.48%)
     
  • CAD/USD

    0.7881
    -0.0021 (-0.27%)
     
  • CRUDE OIL

    73.36
    +0.06 (+0.08%)
     
  • BTC-CAD

    54,008.79
    -2,190.50 (-3.90%)
     
  • CMC Crypto 200

    1,052.38
    -56.54 (-5.10%)
     
  • GOLD FUTURES

    1,754.20
    +4.40 (+0.25%)
     
  • RUSSELL 2000

    2,259.04
    +40.48 (+1.82%)
     
  • 10-Yr Bond

    1.4100
    0.0000 (0.00%)
     
  • NASDAQ futures

    15,216.00
    -87.50 (-0.57%)
     
  • VOLATILITY

    19.92
    -0.95 (-4.55%)
     
  • FTSE

    7,054.62
    -23.73 (-0.34%)
     
  • NIKKEI 225

    30,248.81
    +609.41 (+2.06%)
     
  • CAD/EUR

    0.6714
    -0.0013 (-0.19%)
     

Gossamer Bio to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SAN DIEGO, August 02, 2021--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its second quarter 2021 financial results on Monday, August 9, 2021.

In connection with the earnings release, Gossamer’s management team will host a live conference call and webcast at 4:30 p.m. ET on Monday, August 9, 2021, to discuss the Company’s financial results and provide a corporate update.

Conference ID: 1188932
Domestic Dial-in Number: (833) 646-0603
International Dial-in Number: (929) 517-9782
Live Webcast: https://edge.media-server.com/mmc/p/ruj72hwq

A replay of the audio webcast will be available for 30 days on the Investors section of the Company's website, www.gossamerbio.com.

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210802005611/en/

Contacts

For Investors and Media:
Bryan Giraudo, Chief Financial Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting